ATE403674T1 - Neuer assay für die auftrennung und quantifizierung von hämagglutinin-antigenen - Google Patents

Neuer assay für die auftrennung und quantifizierung von hämagglutinin-antigenen

Info

Publication number
ATE403674T1
ATE403674T1 AT05716900T AT05716900T ATE403674T1 AT E403674 T1 ATE403674 T1 AT E403674T1 AT 05716900 T AT05716900 T AT 05716900T AT 05716900 T AT05716900 T AT 05716900T AT E403674 T1 ATE403674 T1 AT E403674T1
Authority
AT
Austria
Prior art keywords
antigens
methods
quantification
separation
column
Prior art date
Application number
AT05716900T
Other languages
English (en)
Inventor
Fija Lagerwerf
Johan Kapteyn
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE403674T1 publication Critical patent/ATE403674T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/12—Mumps virus; Measles virus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05716900T 2004-03-17 2005-03-03 Neuer assay für die auftrennung und quantifizierung von hämagglutinin-antigenen ATE403674T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2004050318 2004-03-17

Publications (1)

Publication Number Publication Date
ATE403674T1 true ATE403674T1 (de) 2008-08-15

Family

ID=34957414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716900T ATE403674T1 (de) 2004-03-17 2005-03-03 Neuer assay für die auftrennung und quantifizierung von hämagglutinin-antigenen

Country Status (10)

Country Link
US (3) US7638608B2 (de)
EP (1) EP1725581B1 (de)
AT (1) ATE403674T1 (de)
AU (1) AU2005223371B2 (de)
CA (1) CA2560185C (de)
DE (1) DE602005008722D1 (de)
DK (1) DK1725581T3 (de)
ES (1) ES2313310T3 (de)
NZ (1) NZ549776A (de)
WO (1) WO2005090390A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008220B1 (ru) * 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2005223371B2 (en) * 2004-03-17 2011-06-09 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
AU2006243854A1 (en) * 2005-05-02 2006-11-09 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
EP2232258A4 (de) * 2007-12-05 2011-01-05 Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services Verbesserte virale proteinquantifizierung und impfstoffqualitätskontrolle damit
US9086411B2 (en) * 2007-12-27 2015-07-21 Duke University Resin assisted capture of cysteine-modified proteins/peptides and determination of presence and location of modification
JP2012507272A (ja) * 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
US9341623B2 (en) * 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
JP6232373B2 (ja) 2011-04-21 2017-11-15 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ワクチンから抗原を単離し定量する方法
JP2016539314A (ja) 2011-12-12 2016-12-15 ノバルティス アーゲー インフルエンザウイルス血球凝集素のためのアッセイ法
EP3152347A4 (de) 2014-06-04 2018-04-11 Indevr, Inc. Universelles erfassungsarray zur multiplex-subtypspezifischen quantifizierung und stabilitätsbestimmung von influenzaproteinen
WO2016028776A1 (en) * 2014-08-18 2016-02-25 Sanofi Pasteur Biologics Llc Alkylated influenza vaccines
WO2017005880A1 (en) * 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
JP7779858B2 (ja) * 2020-04-29 2025-12-03 エスケー バイオサイエンス カンパニー リミテッド 使い捨て培養工程システムを用いたインフルエンザウイルス生産方法及びインフルエンザウイルス抗原精製条件の迅速確認試験

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
AU2005223371B2 (en) * 2004-03-17 2011-06-09 Crucell Holland B.V. Novel assay for the separation and quantification of hemagglutinin antigens
US7449116B2 (en) * 2004-10-01 2008-11-11 Agilent Technologies, Inc. Methods and systems for protein separation

Also Published As

Publication number Publication date
EP1725581A1 (de) 2006-11-29
US7638608B2 (en) 2009-12-29
AU2005223371A1 (en) 2005-09-29
DK1725581T3 (da) 2008-11-10
CA2560185C (en) 2013-05-07
US20060051742A1 (en) 2006-03-09
CA2560185A1 (en) 2005-09-29
US20070196387A1 (en) 2007-08-23
ES2313310T3 (es) 2009-03-01
NZ549776A (en) 2009-07-31
DE602005008722D1 (de) 2008-09-18
US7687611B2 (en) 2010-03-30
EP1725581B1 (de) 2008-08-06
US8283452B2 (en) 2012-10-09
WO2005090390A1 (en) 2005-09-29
AU2005223371B2 (en) 2011-06-09
US20100041022A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
ATE403674T1 (de) Neuer assay für die auftrennung und quantifizierung von hämagglutinin-antigenen
Slentz et al. Protein proteolysis and the multi-dimensional electrochromatographic separation of histidine-containing peptide fragments on a chip
Gilar et al. Orthogonality of separation in two-dimensional liquid chromatography
Guo et al. Recent advances in bio-affinity chromatography for screening bioactive compounds from natural products
Gaillard et al. Poisoning by plant material: review of human cases and analytical determination of main toxins by high-performance liquid chromatography–(tandem) mass spectrometry
Hsieh et al. Automated analytical system for the examination of protein primary structure
Fortier et al. Integrated microfluidic device for mass spectrometry-based proteomics and its application to biomarker discovery programs
Strausbauch et al. Mechanism of peptide separations by solid phase extraction capillary electrophoresis at low pH
Tan et al. Chip-based solid-phase extraction pretreatment for direct electrospray mass spectrometry analysis using an array of monolithic columns in a polymeric substrate
Fekete et al. Ultra-high-performance liquid chromatography for the characterization of therapeutic proteins
McCalley Overload for ionized solutes in reversed-phase high-performance liquid chromatography
ATE529752T1 (de) Antikörperquantifizierung
Masuda et al. Microscale phosphoproteome analysis of 10 000 cells from human cancer cell lines
AU2003256806A1 (en) Protein interaction difference mapping
Zhou Separation and detection methods for covalent drug–protein adducts
Ding et al. Selective enrichment of glycopeptides from glycoprotein digests using ion-pairing normal-phase liquid chromatography
Xiong et al. Potential of silica monolithic columns in peptide separations
Yuan et al. Integrated platform for proteome profiling with combination of microreversed phase based protein and peptide separation via online solvent exchange and protein digestion
Singer et al. Separation of multiphosphorylated peptide isomers by hydrophilic interaction chromatography on an aminopropyl phase
Emmett et al. Supercritical fluid chromatography reduction of hydrogen/deuterium back exchange in solution-phase hydrogen/deuterium exchange with mass spectrometric analysis
Rucevic et al. Use of short monolithic columns for isolation of low abundance membrane proteins
Asensio-Ramos et al. Nano-liquid chromatography
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
CY1110296T1 (el) Χρηση αμινων ή αμινοξεων ως τροποποιητες κινητης φασης στη χρωματογραφια
WO2005026323A3 (en) Stationary phases and a purification process using the stationary phases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1725581

Country of ref document: EP